Guided by artificial intelligence and powered by a robotic platform, a system developed by MIT researchers moves a step closer to automating the production of small molecules that could be used in medicine, solar energy, and polymer chemistry.
The system, described in the August 8 issue of Science, could free up bench chemists from a variety of routine and time-consuming tasks, and may suggest possibilities for how to make new molecular compounds, according to the study co-leaders Klavs F. Jensen, the Warren K. Lewis Professor of Chemical Engineering, and Timothy F. Jamison, the Robert R. Taylor Professor of Chemistry and associate provost at MIT.
The technology “has the promise to help people cut out all the tedious parts of molecule building,” including looking up potential reaction pathways and building the components of a molecular assembly line each time a new molecule is produced, says Jensen.
“And as a chemist, it may give you inspirations for new reactions that you hadn’t thought about before,” he adds.
Other MIT authors on the Science paper include Connor W. Coley, Dale A. Thomas III, Justin A. M. Lummiss, Jonathan N. Jaworski, Christopher P. Breen, Victor Schultz, Travis Hart, Joshua S. Fishman, Luke Rogers, Hanyu Gao, Robert W. Hicklin, Pieter P. Plehiers, Joshua Byington, John S. Piotti, William H. Green, and A. John Hart.
From inspiration to recipe to finished product
The new system combines three main steps. First, software guided by artificial intelligence suggests a route for synthesizing a molecule, then expert chemists review this route and refine it into a chemical “recipe,” and finally the recipe is sent to a robotic platform that automatically assembles the hardware and performs the reactions that build the molecule.
Coley and his colleagues have been working for more than three years to develop the open-source software suite that suggests and prioritizes possible synthesis routes. At the heart of the software are several neural network models, which the researchers trained on millions of previously published chemical reactions drawn from the Reaxys and U.S. Patent and Trademark Office databases. The software uses these data to identify the reaction transformations and conditions that it believes will be suitable for building a new compound.
“It helps makes high-level decisions about what kinds of intermediates and starting materials to use, and then slightly more detailed analyses about what conditions you might want to use and if those reactions are likely to be successful,” says Coley.
“One of the primary motivations behind the design of the software is that it doesn’t just give you suggestions for molecules we know about or reactions we know about,” he notes. “It can generalize to new molecules that have never been made.”
Image Credit: Connor Coley, Felice Frankel
News This Week
An Oxford-based firm that uses artificial intelligence to develop new medicines has teamed up with a UK national science facility to screen more than 15,000 drugs for their effectiveness as a treatment for Covid-19. [...]
New research has shed light on a crucial biological mechanism that may have helped the coronavirus to infect humans and spread rapidly around the world. A detailed analysis of the virus’s structure shows that [...]
How does the COVID-19 pandemic compare to other infamous viral infections that have plagued us in modern times? It’s a question that’s been asked repeatedly in social media circles in recent weeks as people [...]
There is no vaccine or specific treatment for COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2. Since the outbreak began in late 2019, researchers have been racing to [...]
Corona Virus (COVID 19) Interview with Michael Osterholm an expert in infectious disease epidemiology.
Michael Osterholm is an internationally recognized expert in infectious disease epidemiology. He is Regents Professor, McKnight Presidential Endowed Chair in Public Health, the director of the Center for Infectious Disease Research and Policy [...]
With the new coronavirus spreading from person to person (possibly including from people without symptoms), reaching four continents, and traveling faster than SARS, driving it out of existence is looking increasingly unlikely. It’s still [...]
Wake Forest Institute for Regenerative Medicine (WFIRM) scientists have improved upon the 3D bioprinting technique they developed to engineer skeletal muscle as a potential therapy for replacing diseased or damaged muscle tissue, moving another [...]
An international team of scientists from the University of Southampton, the University of Padova, and the University of Zurich has connected a silicon neuron to a neuron from the rat hippocampus with an artificial [...]
In an insightful 42-minute interview, NMIN’s Scientific Director Dr. Pieter Cullis, a pioneer in liposomal gene and drug delivery, discusses his scientific career with a focus on his contributions to the evolution of [...]
A powerful antibiotic that kills some of the most dangerous drug-resistant bacteria in the world has been discovered using artificial intelligence. The drug works in a different way to existing antibacterials and is the [...]
Artificial intelligence hit a big milestone in January — the first drug designed entirely using artificial intelligence entered human clinical trials. The compound, created by Oxford-based biotech company Exscientia, is aimed at treating obsessive-compulsive [...]
Researchers at the Massachusetts General Hospital (MGH) in the US have uncovered the ‘Achilles’ heel’ of most viruses which plague mankind, and could soon develop a universal vaccine. Vaccine research, development and testing takes [...]
Every age in the history of human civilisation has a signature material, from the Stone Age, to the Bronze and Iron Ages. We might even call today’s information-driven society the Silicon Age. Since the [...]
CRISPR gene-edited immune cells have been injected into three people with advanced cancer without any serious side effects, the first trial of its kind in the US. It is also the first CRISPR cancer [...]
“We’ll have nanobots that… connect our neocortex to a synthetic neocortex in the cloud. Our thinking will be a…. biological and non-biological hybrid.” Ray Kurzweil, TED 2014 UPDATE - February 9 2020 Since [...]